An experimental drug from Stoke Therapeutics reduced the frequency of convulsive seizures in children with a rare form of epilepsy called Dravet syndrome, the company said Friday.
The study results are early and far from conclusive, but show the potential for a novel, RNA-based treatment to target the underlying genetic cause of the devastating childhood disorder, said Stoke CEO Ed Kaye. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/2021/12/03/stoke-therapeutics-drug-childhood-epilepsy-reduces-seizures/
